St. Lukes Hospital Of Duluth
- Type
- Teaching hospital
- Where
- Duluth, MN
- Medicare CCN
- 240047
- Received
- $269,910 in 61 records, 2024 ($7,191 general, $262,719 research)
- Source
- CMS Open Payments search ↗
On this site
- Plan sponsor: ST. LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Federal award recipient: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
- Nonprofit: ST LUKES HOSPITAL OF DULUTH Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 10 | $7,191 |
| 2024 | Research payment | 51 | $262,719 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 5 | $199,855 | 2024 |
| ABBVIE INC. | 24 | $20,372 | 2024 |
| Janssen Research & Development, LLC | 11 | $20,261 | 2024 |
| CSL Behring | 6 | $8,195 | 2024 |
| CardioFocus, Inc. | 1 | $8,000 | 2024 |
| Smith+Nephew, Inc. | 2 | $3,222 | 2024 |
| AstraZeneca UK Limited | 2 | $2,889 | 2024 |
| Philips North America LLC | 1 | $2,145 | 2024 |
| Olympus America Inc. | 1 | $1,670 | 2024 |
| Stryker Corporation | 4 | $1,535 | 2024 |
| Boston Scientific Corporation | 1 | $1,000 | 2024 |
| Linvatec Corporation | 1 | $578 | 2024 |
| Merge Healthcare Incorporated | 2 | $184 | 2024 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 51 | $262,719 |
| Long term medical supply or device loan | 5 | $5,162 |
| Debt forgiveness | 3 | $1,844 |
| Food and Beverage | 2 | $184 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Stryker Corporation | $900 | Long term medical supply or device loan | In-kind items and services | ARISE 1000 Ex Device, PATIENT CARE - PC | 2024 | |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $803 | Research payment | In-kind items and services | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2024 |
| 2024-12-31 | Linvatec Corporation | $578 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2024 | |
| 2024-12-31 | Stryker Corporation | $461 | Long term medical supply or device loan | In-kind items and services | PROCUITY Device, PATIENT HANDLING - PH | 2024 | |
| 2024-12-31 | AstraZeneca UK Limited | $229 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphami | 2024 |
| 2024-12-31 | Stryker Corporation | $117 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Stryker Corporation | $56 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-26 | ABBVIE INC. | $1,035 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-12-19 | ABBVIE INC. | $1,500 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-12-19 | ABBVIE INC. | $900 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-12-19 | ABBVIE INC. | $80 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | $971 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-12-12 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-12-11 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-11-19 | CardioFocus, Inc. | $8,000 | Research payment | Cash or cash equivalent | HeartLight System Device, Atrial Fibrillation | POST APPROVAL STUDY OF THE HEARTLIGHT ENDOSCOPIC ABLATION SYSTEM FOR THE TREATMENT OF ATRIAL FIBRILATION | 2024 |
| 2024-10-23 | ABBVIE INC. | $615 | Research payment | Cash or cash equivalent | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 | |
| 2024-10-08 | Merge Healthcare Incorporated | $84 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2024 | |
| 2024-10-01 | ABBVIE INC. | $297 | Research payment | Cash or cash equivalent | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 | |
| 2024-09-25 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-09-20 | Janssen Research & Development, LLC | $809 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-09-13 | Janssen Research & Development, LLC | $157 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-09-04 | Janssen Research & Development, LLC | $900 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-09-03 | ABBVIE INC. | $1,636 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-07-18 | ABBVIE INC. | $160 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-07-15 | Olympus America Inc. | $1,670 | Debt forgiveness | In-kind items and services | Device | 2024 | |
| 2024-07-03 | ABBVIE INC. | $2,684 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-06-28 | CSL Behring | $3,495 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-06-17 | Janssen Research & Development, LLC | $1,323 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-06-07 | Janssen Research & Development, LLC | $2,075 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-05-16 | Philips North America LLC | $2,145 | Research payment | In-kind items and services | (V016) Eagle Eye Platinum Device, Medical Device | IMPROVE RCT | 2024 |
| 2024-05-16 | ABBVIE INC. | $410 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-05-09 | ABBVIE INC. | $1,000 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-05-09 | ABBVIE INC. | $285 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-05-08 | ABBVIE INC. | $1,342 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-05-07 | ABBVIE INC. | $410 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-04-25 | ABBVIE INC. | $900 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-04-05 | CSL Behring | $1,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-04-05 | CSL Behring | $750 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-04-04 | ABBVIE INC. | $2,684 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-03-20 | Merge Healthcare Incorporated | $100 | Food and Beverage | Cash or cash equivalent | Software Device, Medical Imaging | 2024 | |
| 2024-03-06 | ABBVIE INC. | $600 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-03-06 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-02-29 | AstraZeneca Pharmaceuticals LP | $36,644 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Ste | 2024 |
| 2024-02-23 | Janssen Research & Development, LLC | $644 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-02-21 | Janssen Research & Development, LLC | $911 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-02-05 | CSL Behring | $2,000 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-02-05 | Boston Scientific Corporation | $1,000 | Research payment | Cash or cash equivalent | General - Brady Device, General - Brady_CRM | APPRAISE ATP | 2024 |
| 2024-02-05 | CSL Behring | $600 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-02-05 | CSL Behring | $350 | Research payment | Cash or cash equivalent | A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a | 2024 | |
| 2024-02-02 | Janssen Research & Development, LLC | $10,000 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-01-26 | AstraZeneca UK Limited | $2,660 | Research payment | Cash or cash equivalent | CALQUENCE Drug, Oncology | A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphami | 2024 |
| 2024-01-24 | AstraZeneca Pharmaceuticals LP | $48,699 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab | 2024 |
| 2024-01-19 | AstraZeneca Pharmaceuticals LP | $108,364 | Research payment | Cash or cash equivalent | A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with | 2024 | |
| 2024-01-19 | Janssen Research & Development, LLC | $971 | Research payment | Cash or cash equivalent | 70033093ACS3003 | 2024 | |
| 2024-01-17 | AstraZeneca Pharmaceuticals LP | $5,344 | Research payment | Cash or cash equivalent | IMFINZI Biological, Oncology | A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for t | 2024 |
| 2024-01-11 | ABBVIE INC. | $820 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-01-10 | ABBVIE INC. | $1,513 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a S | 2024 |
| 2024-01-04 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-01-04 | ABBVIE INC. | $250 | Research payment | Cash or cash equivalent | VENCLEXTA Drug, ONCOLOGY | Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in A | 2024 |
| 2024-01-01 | Smith+Nephew, Inc. | $1,614 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2024 | |
| 2024-01-01 | Smith+Nephew, Inc. | $1,608 | Long term medical supply or device loan | In-kind items and services | NA Device, Sports Med Resection | 2024 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Duluth, MN, county St. Louis County, MN, state Minnesota; placed by its city name.
| Measure | Place (city or town) Duluth, MN | County St. Louis County, MN | State Minnesota |
|---|---|---|---|
| Population B01003 | 87,093 | 200,123 | 5,739,445 |
| Population, 2020 census P1 | 86,697 | 200,231 | 5,706,494 |
| Median age B01002 | 35.2 | 41.2 | 38.8 |
| Under 18 B01001 | 17.6% | 18.6% | 22.9% |
| 65 and over B01001 | 17.3% | 21.4% | 17.3% |
| Households B11001 | 37,447 | 87,115 | 2,307,955 |
| Foreign born B05002 | 3.1% | 1.9% | 8.7% |
| Median household income B19013 | $68,807 | $70,069 | $89,062 |
| Median family income B19113 | $102,608 | $95,686 | $113,993 |
| Per capita income B19301 | $41,503 | $41,302 | $48,237 |
| Poverty rate B17001 | 16.8% | 13.2% | 9.3% |
| Unemployment rate B23025 | 4.7% | 4.6% | 4.1% |
| Civilian labor force B23025 | 48,580 | 102,280 | 3,119,042 |
| Mean commute (minutes) B08013 | 17.3 | 19.9 | 22.7 |
| Bachelor's degree or higher B15003 | 44.0% | 33.6% | 39.4% |
| Housing units B25001 | 39,978 | 104,263 | 2,545,030 |
| Owner-occupied B25003 | 59.4% | 71.2% | 72.2% |
| Renters B25003 | 40.6% | 28.8% | 27.8% |
| Median home value B25077 | $242,700 | $221,400 | $329,300 |
| Median gross rent B25064 | $1,087 | $1,013 | $1,280 |
| White, not Hispanic B03002 | 86.6% | 89.5% | 75.9% |
| Black B03002 | 2.7% | 1.6% | 6.9% |
| Hispanic or Latino B03002 | 2.6% | 1.9% | 6.4% |
| Asian B03002 | 1.7% | 1.0% | 5.1% |
| American Indian and Alaska Native B03002 | 1.3% | 1.5% | 0.7% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Duluth, MN.
Comments